| abstract |
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines, substantially without interfering with the anxiolytic, antipsychotic, anticonvulsant, and muscle relaxant activity of benzodiazepines, especially the benzodiazepines used for treatment of diseases where the sedative, hypnotic or respiratory depressive effects are undesirable, such as diseases selected from the group consisting of anxiety, anxiety neurosis, anxiety reactions, panic reactions, schizophrenia, affective or schizoaffective type schizophrenia, borderline psychosis, agitating endogene depressions, hyperactivity in children, and muscle spasms; the use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of schizophrenia, in particular affective or schizoaffective type schizophrenia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a galanthamine derivative. |